Drugs / AB1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05261711 | Dec 2022 → Oct 2024 | sickle cell disease | Nirmish Shah | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AB1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05261711 ↗ |
| Route | Oral | “taken orally” NCT05261711 ↗ |